PBAC's latest decision on Pancreatic extract: Recommended (2020). Considered for Pancreatic enzyme replacement in paediatric and adult patients with Pancreatic Exocrine Insufficiency (PEI), often associated with cystic fibrosis, chronic pancreatitis, pancreatic surgery, gastrointestinal bypass surgery, and ductal obstruction of the pancreas or common bile duct.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2020
Submissions
1
2020 → 2020
Eligible population
Paediatric and adult patients with Pancreatic Exocrine Insufficiency (PEI) requiring pancreatic enzyme replacement therapy, including those with cystic fibrosis, chronic pancreatitis, post-pancreatic/gastrointestinal surgery, or ductal obstruction.
Therapy area
Gastroenterology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Creon capsules
Economic model
BIA only
ICER note
No economic evaluation presented; minor submission with cost-minimisation approach only